Embryonal Rhabdomyosarcoma — Trials

Embryonal Rhabdomyosarcoma — Trials · CancerIndex

Clinical trials

Registered studies

17 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.

Active: 4
Recruiting: 2
Ph III recruiting: 2
Growth YoY: —
Industry share: 0%
Top sponsor: Children's Oncology Group
Termination share: —

Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancers Terminated studies (1)

clinicaltrialsPublishedShowing 1–5 of 5 studies matching the filters · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT03041701	Insulin-like Growth Factor 1 Receptor (IGF-1R) Antibody AMG479 (Ganitumab) in Combination With the Src Family Kinase (SFK) Inhibitor Dasatinib in People With Embryonal and Alveolar Rhabdomyosarcoma	terminated	Phase 1 / Phase 2	14	National Cancer Institute (NCI)NIH	1	Apr 14, 2022	clinicaltrials
NCT00923351	Therapy to Treat Ewing's Sarcoma, Rhabdomyosarcoma or Neuroblastoma	completed	Phase 1 / Phase 2	44	National Cancer Institute (NCI)NIH	1	Jun 15, 2018